Publication

Abstract : Metformin hydrochloride is a biguanide, which is us ed as an oral hypoglycemic agent. It is a white crystalline hygroscopic drug used as an antid iabetic agent specifically for type-2 diabetes mellitus. When given, a divided dose of 0.5-3 gm da ily, it increases the hepatic glucose production thereby increasing the peripheral glucose uptake an d utilization and shows a significant bioavailabili ty about 50-60%. Since metformin hydrochloride is wide ly chosen as the first line drug in the treatment of type2 DM, because of its minimal risk and maximu m efficacy, the formulation of metformin hydrochloride matrix tablet was taken in to conside ration. Matrix tablets reduce the frequency of dose administration, and are found to have increased pat ient compliance. A relatively recent technique called sintering technique is involved in the formu lation which aims to extend the release of metformi n hydrochloride from the matrix tablets. After formul ation the tablets where subjected to preformulation studies, micromeritic studies, stability studies an d other tablet evaluation methods. In the present world diabetes is a haunting threat for life and so , the development of metformin hydrochloride matrix tablets paves the way to increase the quality of life